eligibility_summary
Include: advanced/metastatic solid tumor with FGFR2b expression or FGFR2 amplification, ≥1 measurable lesion, ECOG 0–1, life expectancy ≥3 mo, adequate organs, tumor tissue available. Prior therapy: escalation—no further standard options, expansion—≥1–2 prior lines incl fluoropyrimidine/platinum. Exclude: prior TOP1i- or FGFR2b-ADCs, corneal disease, uncontrolled CNS mets, recent therapy, unresolved AEs, other cancer ≤2 y, ILD/pneumonitis or O2 sat <92%.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06625593 tests BG-C137, an intravenous anti-FGFR2b antibody–drug conjugate (ADC), as monotherapy and in combination with anticancer agents in advanced solid tumors. Mechanism: BG-C137 is a monoclonal antibody that binds the FGFR2b isoform on tumor cells, undergoes receptor-mediated internalization, and releases an intracellular cytotoxic payload to induce tumor cell death, targeting may also attenuate FGFR2 signaling. Targets: tumors with FGFR2b protein expression and/or FGFR2 gene amplification, engaging the FGFR/FGF signaling pathway on FGFR2b-expressing cancer cells. Combination arms evaluate BG-C137 with other anticancer agents to enhance antitumor activity.